𝔖 Bobbio Scriptorium
✦   LIBER   ✦

204 POSTER Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study

✍ Scribed by T.W. Flaig; B.D. Curti; M.S. Gordon; P.J. Van Veldhuizen; W.H. Miller; M.S. Ernstoff; S. Bhatia; N.H. Hunder; N. Royer; J.A. Thompson


Book ID
119599359
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
76 KB
Volume
6
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.